Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Banacha Street 1A, Warsaw, 02-097, Poland.
BMC Surg. 2024 Aug 6;24(1):224. doi: 10.1186/s12893-024-02515-y.
Liver transplantation (LT) is a well-established method applied for the treatment of various liver diseases, including primary and secondary malignancies, as well as acute liver failure triggered by different mechanisms. In turn, liver failure (PHLF) is the most severe complication observed after liver resection (LR). PHLF is an extremely rare indication for LT. The aim of the present study was to assess the results of LT in patients with PHLF.
Relevant cases were extracted from the prospectively collected database of all LTs performed in our center. All clinical variables, details of the perioperative course of each patient and long-term follow-up data were thoroughly assessed.
Between January 2000 and August 2023, 2703 LTs were carried out. Among them, six patients underwent LT for PHLF, which accounted for 0.2% of all patients. The median age of the patients was 38 years (range 24-66 years). All patients underwent major liver resection before listing for LT. The 90-day mortality after LT was 66.7% (4 out of 6 patients), and all patients experienced complications in the posttransplant course. One patient required early retransplantation due to primary non-function (PNF). The last two transplanted patients are alive at 7 years and 12 months after LT, respectively.
In an unselected population of patients with PHLF, LT is a very morbid procedure associated with high mortality but should be considered the only life-saving option in this group.
肝移植(LT)是一种成熟的方法,用于治疗各种肝脏疾病,包括原发性和继发性恶性肿瘤,以及由不同机制引起的急性肝功能衰竭。相反,肝功能衰竭(PHLF)是肝切除(LR)后观察到的最严重的并发症。PHLF 是 LT 的极罕见指征。本研究旨在评估 LT 在 PHLF 患者中的结果。
从我们中心进行的所有 LT 的前瞻性收集数据库中提取相关病例。彻底评估了每位患者的所有临床变量、围手术期过程细节和长期随访数据。
2000 年 1 月至 2023 年 8 月期间,共进行了 2703 例 LT。其中,6 例患者因 PHLF 接受 LT,占所有患者的 0.2%。患者的中位年龄为 38 岁(范围 24-66 岁)。所有患者在 LT 列入名单前均接受了主要肝切除术。LT 后 90 天死亡率为 66.7%(6 例中有 4 例),所有患者在移植后均出现并发症。1 例患者因原发性无功能(PNF)需要早期再次移植。最后两名接受移植的患者分别在 LT 后 7 年和 12 个月时存活。
在未选择的 PHLF 患者人群中,LT 是一种非常病态的程序,死亡率很高,但应被视为该组患者的唯一救命选择。